AstraZeneca
Crestor victory lifts AstraZeneca
July 1, 2010Sales and Marketing AstraZeneca, Crestor
AstraZeneca has defeated a challenge to the US patent on its blockbuster cholesterol drug Crestor. A US District Judge in …
AstraZeneca and Targacept begin depression trials
June 24, 2010Research and Development AstraZeneca, Targacept, depression
AstraZeneca and Targacept have begun enrolling patients in phase III trials for TC-5214, a new treatment for depression. The new …
MedImmune Ventures appoints Ron Laufer
June 18, 2010Research and Development AstraZeneca, MedImmune, appointment, research and development
Ron Laufer has joined MedImmune’s venture capital arm as senior managing director. The company, which is the worldwide biologics unit …
Zactima promising in rare thyroid cancer
June 11, 2010Research and Development, Sales and Marketing AstraZeneca, thyroid cancer, zactima
AstraZeneca’s Zactima (vandetanib) will be filed with regulators later this year as a treatment for thyroid cancer after promising results. …
AZ submits Nexium-aspirin combination for EU approval
June 7, 2010Sales and Marketing AstraZeneca, Nexium, aspirin
AstraZeneca is seeking European approval for a new version of its anti-ulcer blockbuster Nexium that combines the pill with aspirin. …
Pfizer R&D head exits for AstraZeneca
May 27, 2010Research and Development AstraZeneca, Pfizer, appointment, research and development
One of Pfizer’s two heads of research and development Martin Mackay is to leave the company for rivals AstraZeneca. Only …
AZ signs tuberculosis drug discovery deal
May 6, 2010Research and Development AstraZeneca, India, TB, tuberculosis
AstraZeneca and the Global Alliance for TB Drug Development are to collaborate on the discovery and development of drugs to treat tuberculosis.The two …
Crestor gains prevention licence in Europe
April 27, 2010Sales and Marketing AstraZeneca, Crestor, statin
AstraZeneca’s statin treatment Crestor has been approved in the European Union for the prevention of major cardiovascular events in patients …
European approval for ‘double strength’ Faslodex
March 19, 2010Sales and Marketing AstraZeneca, Faslodex, breast cancer
AstraZeneca’s Faslodex has expanded its European licence after winning approval to treat women with hormone receptor-positive breast cancer in a …
UK hit hard as AstraZeneca reveals R&D cuts
March 3, 2010Research and Development AstraZeneca, job cuts
Nearly 3,500 R&D jobs will be affected at AstraZeneca in the coming months as the pharmaceutical giant exits discovery research …
Brennan rejects generics diversification model
February 11, 2010Sales and Marketing AstraZeneca, biosimilars, em, generics, industry
AstraZeneca’s chief executive David Brennan has rejected the strategy of diversification into generics and biosimilars being pursued by many of …
Job cuts at GlaxoSmithKline and AstraZeneca
February 2, 2010Research and Development, Sales and Marketing AstraZeneca, GlaxoSmithKline
Britain’s two biggest pharma companies GlaxoSmithKline and AstraZeneca are poised to make deep job cuts as business models continue to …
BBC highlights AZ’s Seroquel woes
January 27, 2010Sales and Marketing AstraZeneca, Seroquel, industry reputation
AstraZeneca’s ongoing US legal battle over its antipsychotic drug Seroquel was highlighted this week in a BBC radio programme. AstraZeneca …
AstraZeneca continues personalised healthcare push
January 19, 2010Sales and Marketing AstraZeneca, Dako, Diagnostics, Iressa
AstraZeneca and cancer diagnostics specialist Dako Denmark are to develop companion diagnostics for a number of the pharma company’s oncology …
AstraZeneca taps Korean firm for antibiotics
January 15, 2010Research and Development Asia, AstraZeneca, CrystalGenomics, Korea, anti-infectives
AstraZeneca has signed another licensing deal to bolster its anti-infectives business, this time signing a deal with Korean company CrystalGenomics …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
